6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid | 801315-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
• 英文别名: 6-cyclopentylsulfonyl-4-oxo-1H-quinoline-3-carboxylic acid
• CAS: 801315-17-3
• 化学式: C₁₅H₁₅NO₅S
• 分子量: 321.354
• InChiKey: DBXMFMANVUVVOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration

  摘要：

  Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable pro. le for inhaled dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.012
• 作为产物：
  描述：

  ethyl 6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylate 在 水 、 乙酸乙酯 作用下， 以 乙醇 、 sodium hydroxide 为溶剂， 反应 19.0h， 以to give the title compound as a beige solid (9.47 g)的产率得到6-(cyclopentylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
  参考文献：
  名称：

  Quinoline derivatives as phosphodiesterase inhibitors

  摘要：

  根据本发明，提供了式（I）的新化合物或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，并提供了制备它们的方法、含有它们的配方以及它们在治疗炎症性疾病方面的用途。

  公开号：

  US20070049570A1

文献信息

• [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004103998A1

  公开（公告）日：2004-12-02

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Barker David Michael

  公开号：US20060178416A1

  公开（公告）日：2006-08-10

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了公式(I)的新化合物或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、包含它们的制剂和它们在治疗炎症性疾病方面的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：GLAXO GROUP LIMITED

  公开号：EP1944305A1

  公开（公告）日：2008-07-16

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了式 (I) 的新型化合物或其药学上可接受的盐类（其中 R1、R2、R19、R20 和 R34 如说明书所述）、制备它们的工艺、含有它们的制剂以及它们在治疗炎症性疾病中的用途。
• QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1633748A1

  公开（公告）日：2006-03-15